UCB, Speakers bureau: Consultancy / speaker fees from: Abbvie, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, UCB, Susanne Lüders: None declared, Judith Rademacher: None declared, Hildrun Haibel Consultant of: Abbvie, BMS, Celgene, Lilly, MSD, Novartis, Pfizer. Roche, UCB, Speakers bureau: Abbvie, CED Service GmbH, Falk, Ferring, Janssen, Novartis, Takeda, Speakers bureau: Abbvie, CED Service GmbH, Falk, Ferring, Janssen, Novartis, Takeda (BS served as representative of the Charité), Denis Podubny Grant/research support from: Abbvie, MSD, Novartis, and Pfizer, Consultant of: Abbvie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB, Speakers bureau: Abbvie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB, Speakers bureau: Abbvie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB, Speakers bureau: Abbvie, BMS, Celgene, Lilly, MSD, Pfizer, Roche, UCB, Speakers bureau: Abbvie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB, Speakers bureau: Abbvie, Bristol-Myers Squibb, Eli Lilly, MSD, Pfizer.

Disclosure of Interests: Carlos Tornero: None declared, María del Carmen Castro Villegas: None declared, Javier Juanola-Rowa: None declared, María Luz García-Viver: None declared, Cristina Fernández-Carbajalido Consultant of: Yes, I have received fees for scientific advice (Abbvie, Celgene, Janssen, Lilly and Novartis), Speakers bureau: Yes, I have received fees as a speaker (Abbvie, Celgene, Janssen, Lilly, MSD, Novartis), Jose Francisco García LLorente: None declared, Beatriz Joven-Ibáñez Speakers bureau: Abbvie, Celgene, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, E. Galindez: None declared, Claudia Urrego-Laurín: None declared,,Eugene de Miguel Grant/research support from: Yes (Abbvie, Novartis, Pfizer), Consultant of: Yes (Abbvie, Novartis, Pfizer), Paid instructor for: yes (Abbvie, Novartis, Pfizer, MSD, UCB, Roche, Grunental, Janssen, Sanofi). Speakers bureau: yes (Abbvie, Novartis, Pfizer, MSD, UCB, Roche, Grunental, Janssen, Sanofi).

DOI: 10.1136/annrheumdis-2020-eular.5450

FR10325 UVEITIS OCCURRENCE IN EARLY INFLAMMATORY BACK PAIN, FIVE YEARS DATA FROM A PROSPECTIVE FRENCH NATIONWIDE COHORT

D. Wendling1, C. Pratil1, T. Lequerre2, C. Micolle Richard3, M. Douagos3, A. Moltó3, X. Guilhout1, CHU, University Teaching Hospital, Rheumatology, Besançon, France; 2CHU, University Teaching Hospital, Rheumatology, Rouen, France; 3Cochin Hospital, Rheumatology, Paris, France; 4CHU, University Teaching Hospital, Rheumatology, Saint Denis de la Réunion, Reunion Island

Background: Uveitis is the most frequent extra rheumatological manifestation in axial Spondyloarthritis (SpA). DESIR is a prospective multicenter cohort of patients with early inflammatory back pain suggestive of SpA. We reported previously a 8.5% baseline prevalence of uveitis for the patients included in the cohort; this history of uveitis at the first visit of the cohort was associated with inflammatory bowel disease (IBD) and preceding infection (1).

Objectives: The aim of the study was to evaluate the prevalence and incidence of uveitis over the first five years of prospective follow-up of the cohort, and to evaluate its associated factors.

Methods: DESIR is a prospective observational cohort of patients with recent onset inflammatory back pain (more than 3 months, less than 3 years), suggestive of axial SpA. All available factors in the database were compared between patients with and without uveitis at 5 years, by uni and then multivariate analysis. Baseline factors associated with new cases of uveitis occurrence over the 5 years were also analyzed. Significance: p less than 0.05.

Results: After 5 years, 91 patients (out of 480 with complete follow-up) had at least one uveitis episode, giving an estimated prevalence of 18.9% [95%CI: 15.4-22.4]. In multivariate analysis, uveitis was associated with dactylitis (OR 2.92 [2.06 – 4.14]; p=0.002*), ESR > 7mm (medium value) (OR 2.19 [1.57 – 3.06]; p=0.018*).

New incident uveits occurred in 31 cases over 5 years, giving an estimated incidence rate of 1.29 [0.84 – 1.74] / 100 patient-years. New incidence of uveitis was